← All trials
NCT04973137
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Jul 22, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Prothena Biosciences IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.